Structure-based in silico approaches for drug discovery against Mycobacterium tuberculosis
Mycobacterium tuberculosis is the causative agent of TB and was estimated to cause 1.4 million death in 2019, alongside 10 million new infections. Drug resistance is a growing issue, with multi-drug resistant infections representing 3.3% of all new infections, hence novel antimycobacterial drugs are...
Main Authors: | Alexander D.H. Kingdon, Luke J. Alderwick |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037021002725 |
Similar Items
-
In Silico Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis
by: Kirsten E. Knoll, et al.
Published: (2022-04-01) -
In silico discovery and in vitro activity of inhibitors against Mycobacterium tuberculosis 7,8-diaminopelargonic acid synthase (Mtb BioA)
by: Billones JB, et al.
Published: (2017-03-01) -
Predictive Power of In Silico Approach to Evaluate Chemicals against <i>M. tuberculosis</i>: A Systematic Review
by: Giulia Oliveira Timo, et al.
Published: (2019-09-01) -
Pangenome Analysis of <i>Mycobacterium tuberculosis</i> Reveals Core-Drug Targets and Screening of Promising Lead Compounds for Drug Discovery
by: Hamza Arshad Dar, et al.
Published: (2020-11-01) -
Editorial: Drug-resistant Mycobacterium tuberculosis
by: Helena I. M. Boshoff, et al.
Published: (2023-05-01)